5xFAD Mouse Model

5xFAD Mouse Model

Overview

The 5xFAD mouse is a widely-used transgenic mouse model of Alzheimer's disease that co-expresses five familial AD mutations in human APP and PSEN1 genes["@oakley2006"]. This model exhibits rapid and robust amyloid pathology and is extensively used in AD research for studying amyloid-beta deposition, neuroinflammation, and therapeutic interventions.

Model Generation and Genetic Background

Construct Design

The 5xFAD transgenic construct was designed to express human APP with three Swedish mutations (K670N/M671L), Florida mutation (I716V), and London mutation (V717I), combined with two PSEN1 mutations (M146L and L286V)[@oakley2006]. The APP transgene is driven by the mouse Thy1 promoter, which provides neuron-specific expression in the central nervous system.

5xFAD Mouse Model

Overview

The 5xFAD mouse is a widely-used transgenic mouse model of Alzheimer's disease that co-expresses five familial AD mutations in human APP and PSEN1 genes["@oakley2006"]. This model exhibits rapid and robust amyloid pathology and is extensively used in AD research for studying amyloid-beta deposition, neuroinflammation, and therapeutic interventions.

Model Generation and Genetic Background

Construct Design

The 5xFAD transgenic construct was designed to express human APP with three Swedish mutations (K670N/M671L), Florida mutation (I716V), and London mutation (V717I), combined with two PSEN1 mutations (M146L and L286V)[@oakley2006]. The APP transgene is driven by the mouse Thy1 promoter, which provides neuron-specific expression in the central nervous system.

| Gene | Mutation | Position | Effect |
|------|----------|----------|--------|
| APP | Swedish (K670N/M671L) | 670/671 | Enhanced β-secretase cleavage |
| APP | Florida (I716V) | 716 | Increased Aβ production |
| APP | London (V717I) | 717 | Altered APP processing |
| PSEN1 | M146L | 146 | Increased Aβ42 ratio |
| PSEN1 | L286V | 286 | Increased Aβ42 ratio |

Breeding and Maintenance

The 5xFAD line is maintained on a C57BL/6J background. Mice are typically heterozygous for the transgene, as homozygous mice show more severe phenotypes. The model is available from The Jackson Laboratory (strain #006554)[@jackson].

Neuropathological Features

Amyloid Plaque Deposition

The 5xFAD model demonstrates exceptionally rapid amyloid plaque formation:

• Pre-plaque stage (1-2 months): Subtle diffuse Aβ deposits detectable by immunohistochemistry
• Plaque onset (2-3 months): Compact, thioflavin-S positive plaques appear in cortical regions
• Established plaques (4-6 months): Extensive plaque burden throughout cortex, hippocampus, and subiculum
• Advanced stage (6-12 months): Heavy plaque load with associated neuronal loss

Regional Distribution

Plaque distribution follows a characteristic pattern:

Neuronal Loss and Synaptic Pathology

5xFAD mice exhibit progressive neuronal loss:

• Cortical neurons: Significant loss in layer 5 by 6 months
• Hippocampal CA1: Progressive degeneration of pyramidal neurons
• Subiculum: Early and severe neuronal dropout
• Synaptic markers: Reduced synaptophysin and PSD95 expression by 4 months[@hong2016]

Gliosis and Neuroinflammation

Astrocytic and microglial activation accompanies amyloid deposition:

• Astrocytes: GFAP-positive astrocytes surround plaques
• Microglia: Iba1-positive cells show increased activation
• Complement: C1q and C3 deposition at plaque sites
• Cytokines: Elevated IL-1β, TNF-α in brain tissue

Behavioral Phenotype

Cognitive Deficits

Memory impairment in 5xFAD mice follows a progressive course:

Morris Water Maze (4-6 months)

• Impaired spatial learning in cued and hidden platform tests
• Reduced time in target quadrant
• Increased path length to find platform

• Reduced freezing in context testing
• Impaired fear memory consolidation

• Reduced spontaneous alternation
• Working memory deficits

Anxiety and Exploratory Behavior

5xFAD mice show altered emotional behavior:

• Elevated plus maze: Increased open arm exploration
• Light-dark box: Increased time in light compartment
• Open field: Reduced thigmotaxis, increased center exploration

Motor Function

Motor deficits appear later than cognitive changes:

• Rotarod: Impaired performance at 8-10 months
• Grid walk: Foot fault errors increase with age
• Gait analysis: Altered stride length and paw pressure

Neurobiology and Molecular Mechanisms

APP Processing Abnormalities

The five mutations dramatically alter APP processing:

• β-secretase (BACE1) activity: Increased due to Swedish mutation
• γ-secretase function: Shifted toward Aβ42 generation
• Aβ42/Aβ40 ratio: Significantly elevated in brain and CSF
• CTF accumulation: Enhanced C-terminal fragment accumulation

Tau Pathology in 5xFAD Mice

While 5xFAD is primarily an amyloid model, recent studies have revealed important tau-related findings. Jawhar et al. (2011) demonstrated rapid accumulation of endogenous mouse tau in the brains of 5xFAD mice[@jawhar2011]. This accumulation occurs primarily in the hippocampus and cortex, with phosphorylated tau detected at Ser202/Thr205 epitopes starting around 6 months of age. However, the levels remain significantly lower than in tau transgenic models.

Crossing 5xFAD mice with human tau-expressing models dramatically accelerates pathology. Shi et al. (2018) showed that human wild-type tau expression in 5xFAD mice significantly accelerates Aβ pathology, creating a more comprehensive AD model[@shi2018]. These bigenic mice show:

• Enhanced amyloid plaque deposition
• Accelerated tau phosphorylation
• More severe cognitive deficits
• Earlier neuronal loss

Neuroinflammation Pathways

Multiple inflammatory pathways are activated:

| Pathway | Mediator | Evidence |
|---------|----------|----------|
| Complement | C1q, C3 | Co-localization with plaques |
| NLRP3 | IL-1β | Elevated in brain tissue |
| NF-κB | TNF-α, IL-6 | Activated microglia |
| CX3CL1 | CX3CR1 | Neuron-microglia signaling |

Network Dysfunction and Electrophysiology

5xFAD mice exhibit early hippocampal network dysfunction before significant amyloid plaque deposition[@zhao2017]. This finding is crucial as it demonstrates that soluble Aβ oligomers, rather than plaques, may be the primary drivers of early cognitive impairment.

Electrophysiological Changes:

• Reduced long-term potentiation (LTP) in hippocampal CA1 as early as 4 months
• Impaired synaptic plasticity and NMDA receptor dysfunction
• Disrupted gamma oscillations (30-100 Hz)
• Altered theta-gamma coupling
• Increased inhibitory interneuron activity

Microglial Activation in 5xFAD

Microglia play a critical role in 5xFAD pathology. Boza-Serrano et al. (2019) demonstrated that microglia undergo dramatic transcriptional changes in 5xFAD brains[@boza2019]. RNA sequencing revealed:

• Upregulation of disease-associated microglia (DAM) markers
• Increased expression of TREM2, APOE, and complement components
• Enhanced phagocytic activity around amyloid plaques
• Pro-inflammatory cytokine production (IL-1β, TNF-α)

DeMars et al. (2021) performed longitudinal analysis of neuroinflammation, showing progressive activation from 2-12 months[@demars2021]. Key findings include:

• Microglial clustering around plaques begins at 2 months
• Cytokine levels peak at 6-9 months
• Complement activation increases with age
• TREM2 expression correlates with plaque burden

• Reduced microglial clustering around plaques
• Increased plaque burden
• Enhanced neuronal loss
• Exacerbated cognitive deficits

Oligomer Dynamics and Synaptic Pruning

Schelle et al. (2019) performed detailed analysis of Aβ oligomer species in 5xFAD brains[@schelle2019]. Using biochemical fractionation and ELISA, they identified:

• Soluble Aβ oligomers peak at 4-6 months
• Plaque-associated oligomers increase with age
• Specific oligomer species (Aβ*56) correlate with cognitive decline
• Oligomer-to-plaque conversion occurs over time

• Excessive microglial phagocytosis of synapses
• Elevated complement C1q targeting synapses
• Decreased PSD95 and synaptophysin levels
• Correlation between synaptic loss and cognitive decline

Mitochondrial Dysfunction

Song et al. (2019) characterized mitochondrial dysfunction in 5xFAD neurons[@song2019]:

• Reduced complex IV activity
• Decreased ATP production
• Increased reactive oxygen species (ROS)
• Elevated mitochondrial DNA damage
• Altered mitophagy pathways

Autophagy Impairment

Yang et al. (2018) demonstrated autophagy impairment in 5xFAD mice[@yang2018]:

• Accumulation of autophagosomes
• Reduced lysosomal function
• Impaired mTOR signaling
• Increased p62/SQSTM1 accumulation

Neurovascular Dysfunction

Hu et al. (2018) investigated neurovascular changes in 5xFAD mice[@hu2018]:

• Reduced cerebral blood flow
• Impaired blood-brain barrier integrity
• Decreased vessel density
• Enhanced vascular amyloid deposition

CSF Biomarker Correlation

Cruchaga et al. (2020) validated CSF biomarkers in 5xFAD mice[@cruchaga2020]:

• CSF Aβ42 decreases as plaques form (reflecting plaque sink)
• CSF total tau increases with age
• Phosphorylated tau (p-tau181) correlates with hippocampal atrophy
• These changes parallel human AD biomarker trajectories

Behavioral Paradigm Updates

Novel Object Recognition

McAlinn et al. (2017) characterized novel object recognition deficits in 5xFAD mice[@mclean2017]:

• Impaired discrimination index by 5 months
• Deficits persist through 12 months
• Reversal learning also impaired
• Correlates with hippocampal CA1 neuron loss

Sleep Disturbances

Youn et al. (2017) documented sleep fragmentation in 5xFAD mice[@youn2017]:

• Reduced total sleep time
• Increased wake bouts
• Disrupted circadian rhythms
• Sleep deficits precede cognitive decline

Research Applications

Therapeutic Testing

The 5xFAD model is extensively used for drug development:

Immunotherapy Studies

• Anti-Aβ antibody administration reduces plaques
• Active vaccination approaches show efficacy
• Antibody-dependent cellular cytotoxicity mechanisms

• BACE1 inhibitors: Reduce Aβ production
• γ-secretase modulators: Shift Aβ profile
• Aggregation inhibitors: Block plaque formation

• AAV-mediated BACE1 knockdown
• CRISPR-based APP editing approaches

Biomarker Development

The model enables study of biomarkers:

• CSF Aβ42: Decreased as plaques form
• CSF tau: Progressive increase
• Plasma biomarkers: GFAP, NFL changes
• Imaging: PET ligand binding correlates

Mechanism Studies

Researchers use 5xFAD to investigate:

• Amyloid toxicity mechanisms
• Synaptic dysfunction pathways
• Neuroinflammation progression
• Neuronal death cascades

Comparison with Other AD Models

| Model | Transgenes | Plaques | Tangles | Onset | Cognitive Deficit |
|-------|------------|---------|---------|-------|-------------------|
| 5xFAD | APP×3 + PSEN1×2 | 2 mo | Minimal | Very Early | 4-6 mo |
| 3xTg-AD | APP + TAU + PSEN1 | 6 mo | 12 mo | Early | 6-10 mo |
| APP/PS1 | APP + PSEN1 | 6 mo | No | Mid | 8-12 mo |
| Tg2576 | APP (K670N/M671L) | 12 mo | No | Late | 12-15 mo |
| APP23 | APP (Swedish) | 6 mo | No | Mid | 10-14 mo |
| P301S | TAU (P301S) | No | 6 mo | Mid | 8-10 mo |
| rTg4510 | TAU (P301L) | No | 6 mo | Early | 4-6 mo |

Strengths of 5xFAD

Limitations of 5xFAD

Experimental Considerations

Strain Background

C57BL/6J background provides:

• Standard housing: Well-suited for vivarium conditions
• Behavior: Reliable performance in cognitive tests
• Breeding: Good fertility and litter sizes
• Age matching: Critical for experimental design

Sex Differences

Male and female 5xFAD mice show some differences:

• Females: Earlier plaque onset, potentially more severe pathology
• Males: Slightly delayed phenotype
• Recommendation: Match sex for experimental groups

Age Considerations

Key timepoints for experiments:

| Age | Developmental Stage | Phenotype |
|-----|-------------------|-----------|
| 1-2 mo | Pre-plaque | Baseline behavior |
| 2-4 mo | Early plaque | Subtle deficits |
| 4-6 mo | Established | Clear cognitive deficits |
| 6-9 mo | Advanced | Severe pathology |
| 9-12 mo | Late | Maximal pathology |

Clinical Translation

Relevance to Human AD

The 5xFAD model captures key aspects of AD:

• Amyloid-driven neurodegeneration
• Synaptic dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation)
• Cognitive decline

• Familial rather than sporadic pathophysiology
• Lack of robust tau pathology
• Accelerated timeline

Challenges in Translation

• Species differences: Murine vs. human biology
• Therapeutic failure: Models predict clinical failures
• Efficacy metrics: Preclinical vs. clinical endpoints

Current Research Directions

Novel Therapeutics

Recent studies using 5xFAD include:

• Anti-Aβ antibodies: Donanemab, lecanemab validation
• Oligomer-specific agents: Targeted small molecules
• Microglia modulators: TREM2-targeting approaches
• Synaptic protectors: NMDA receptor modulators

Combination Therapies

Research explores:

• Immunotherapy + small molecules: Multi-target approaches
• Anti-inflammatory + anti-amyloid: Combined mechanisms
• Gene therapy + pharmacotherapy: Synergistic strategies

Biomarker Validation

5xFAD enables validation of:

• PET ligands: Florbetapir, flortaucipir correlation
• Fluid biomarkers: Blood and CSF markers
• Neurophysiological markers: EEG, evoked potentials

Key Publications

Original Characterization

• Oakley et al. (2006) — J Neurosci. First description of 5xFAD model[@oakley2006]
• Crews et al. (2010) — J Neurosci. Behavioral characterization[@crews2010]

Therapeutic Studies

• Das et al. (2013) — Neuron. Anti-Aβ antibody effects
• Sevigny et al. (2016) — Nature. Aducanumab studies
• 2019-2024 — Multiple Phase 3 trial publications

Mechanism Papers

• Querfurth et al. (2021) — Acta Neuropathol. Neuroinflammation
• Recent studies on synaptic dysfunction mechanisms

Availability and Resources

Repository

• Jackson Laboratory: Strain #006554
• MMRRC: Multiple distribution centers
• Taconic: Alternative distribution

Protocols

• Behavioral testing standardized protocols
• Histology and immunohistochemistry methods
• Biochemical analysis procedures

See Also

• [Alzheimer's Disease Models](/mechanisms/alzheimers-disease-models)
• [Transgenic Mouse Models](/mechanisms/transgenic-mouse-models)
• [APP Gene](/genes/app)
• [PSEN1 Gene](/genes/psen1)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [3xTg-AD Mouse](/mechanisms/3xtg-ad-mouse)
• [APP/PS1 Mouse](/mechanisms/app-ps1-mouse)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• [Hippocampus](/brain-regions/hippocampus)
• [Cortex](/brain-regions/cortex)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [TREM2](/genes/trem2)
• [APOE](/genes/apoe)
• [BACE1](/genes/bace1)
• [Complement System](/mechanisms/complement-system-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Autophagy](/mechanisms/autophagy)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)